ImmunityBio (IBRX) was a top loser this quarter, falling -18.95%. Expect a Downtrend continuation
ImmunityBio (IBRX) has had a tough quarter, falling by almost 19%. Despite this, there may be some hope for the stock, as the Aroon Indicator has recently triggered a bullish signal.
First, let's take a look at the earnings results for ImmunityBio. Unfortunately, there is no specific mention of earnings in the provided information. However, it is important to note that earnings reports can greatly impact the stock price of a company. A company's earnings can affect its stock price in a few ways. Positive earnings can lead to an increase in demand for a stock, while negative earnings can lead to a decrease in demand.
Moving on to the technical analysis, the Aroon Indicator is a popular indicator that can help traders identify potential changes in trend. It consists of two lines: the AroonUp line, which measures the strength of the uptrend, and the AroonDown line, which measures the strength of the downtrend. When the AroonUp line crosses above the AroonDown line, it is a bullish signal.
According to the provided information, IBRX's Aroon Indicator triggered a bullish signal on May 01, 2023. This means that the AroonUp line is above 70 while the AroonDown line is below 30, indicating that the stock could be setting up for a bullish move. In fact, historical data shows that in 168 of 188 similar instances where the Aroon Indicator showed a similar pattern, the stock moved higher in the days that followed, putting the odds of a move higher at 89%.
However, it is important to note that past performance is not always indicative of future results. While the Aroon Indicator may be indicating a potential move higher for IBRX, there are other factors that could impact the stock's performance. Additionally, the odds of a downtrend continuation for IBRX are relatively high at 58%.
While the recent Aroon Indicator signal may be a positive sign for IBRX, it is important for investors to consider all available information before making any investment decisions. The stock has had a tough quarter, and while historical data suggests a potential move higher, there are still risks involved.
IBRX in +6.44% Uptrend, advancing for three consecutive days on November 24, 2025
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IBRX advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IBRX's RSI Indicator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 68 cases where IBRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on November 26, 2025. You may want to consider a long position or call options on IBRX as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IBRX just turned positive on November 21, 2025. Looking at past instances where IBRX's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .
IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
IBRX moved below its 50-day moving average on October 29, 2025 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for IBRX entered a downward trend on November 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (27.349). P/E Ratio (0.000) is within average values for comparable stocks, (52.390). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.898). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (22.026) is also within normal values, averaging (331.774).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IBRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of cancer treatment products
Industry Biotechnology
Advertisement